Hypersensitivity reactions to recombinant tissue plasminogen activator.

Area of Science:

• Neurology
• Pharmacology
• Immunology

Background:

• Recombinant tissue plasminogen activator (rtPA) is the standard thrombolytic for acute ischemic stroke.
• Hypersensitivity reactions, including orolingual angioedema, are potential adverse effects of rtPA.
• Orolingual angioedema, though infrequent, can be severe and airway-compromising.

Purpose of the Study:

• To review the current understanding of rtPA-induced orolingual angioedema.
• To explore the underlying mechanisms, particularly the role of bradykinin.
• To discuss potential treatment strategies and the importance of monitoring.

Main Methods:

• Literature review of studies on rtPA-induced angioedema.
• Analysis of evidence regarding the pathophysiology of angioedema.
• Synthesis of clinical observations and treatment outcomes.

Main Results:

• Emerging evidence suggests bradykinin generation is the primary driver of rtPA-induced orolingual angioedema.
• Anaphylactic mechanisms are less implicated than previously thought.
• Standard antianaphylactic treatments may be ineffective in some cases.

Conclusions:

• rtPA-induced orolingual angioedema is likely bradykinin-mediated.
• Bradykinin B2 receptor antagonists show promise for refractory cases.
• Close monitoring and proportionate management are crucial due to potential airway compromise.